clinical trial · NCT07093580
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
Healthy ParticipantsS-892216-LAIPlacebo
brief summary
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
started
Jul 29, 2025
primary completion
Jun 30, 2028
completion
Jun 30, 2028
last updated
Oct 16, 2026
official title
Phase 1 Study of a Long-acting Injectable S-892216 in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol